Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

Dose-ranging study evaluating potential first- and best-in-class inhaled pan-JAK inhibitor in patients receiving medium-to-high dose ICS/LABA therapy

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced the first patient has been dosed in its Phase 2b clinical trial evaluating frevecitinib, a novel inhaled pan JAK inhibitor, in patients with severe asthma inadequately controlled despite treatment with medium-to-high dose inhaled corticosteroid long-acting beta agonist (ICS/LABA) therapy.

PANAIRAMA is a randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate the efficacy, safety and pharmacokinetics of three doses of frevecitinib. The study is intended to identify the optimal dose regimen to support future pivotal clinical development. The trial will enroll patients across multiple clinical sites in the United States and internationally. Additional information about the PANAIRAMA study is available at ClinicalTrials.gov under identifier NCT07532265.